# Rhu-pGSN for Acute Respiratory Distress Syndrome (ARDS)

> **NCT05947955** · PHASE2 · RECRUITING · sponsor: **BioAegis Therapeutics Inc.** · enrollment: 600 (estimated)

## Conditions studied

- Acute Respiratory Distress Syndrome
- Infections

## Interventions

- **DRUG:** Rhu-pGSN
- **DRUG:** normal saline

## Key facts

- **NCT ID:** NCT05947955
- **Lead sponsor:** BioAegis Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-03
- **Primary completion:** 2026-10-01
- **Final completion:** 2027-03-01
- **Target enrollment:** 600 (ESTIMATED)
- **Last updated:** 2026-01-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05947955

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05947955, "Rhu-pGSN for Acute Respiratory Distress Syndrome (ARDS)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05947955. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*